HK Stock Market Move | Biocytogen Pharmaceuticals-B(02315) rose over 6% in the afternoon. The 25-year performance forecast is bright, and external authorization opens up long-term growth prospects.

Biocytogen Pharmaceuticals-B (02315) rose by over 6% in the afternoon, rising by 6.33% to 52.95 Hong Kong dollars as of the time of publication, with a turnover of 34.0299 million Hong Kong dollars. On the news front, Biocytogen Pharmaceuticals recently announced its performance forecast for 2025, expecting to achieve annual revenue of approximately 1.369 billion to 1.389 billion yuan, a year-on-year increase of 39.61% to 41.65%; and expecting to achieve a net profit attributable to the parent company of approximately 162 million to 182 million yuan, a significant year-on-year increase of 384.26% to 443.88%. Guolian Minsheng Securities released a research report stating that due to the innovative advantages of the model animal and preclinical CRO business, as well as the antibody platform advantage supported by the "thousand mice and ten thousand antigens" plan, Biocytogen Pharmaceuticals' performance in 2025 is impressive. The report pointed out that since 2025, the company has reached external agreements with several leading pharmaceutical companies at home and abroad, and several pipelines have obtained IND approvals. With the progress of authorized pipelines, the company is expected to receive milestone payments and other income, further opening up growth opportunities.